drugset / Trial / NCT00115960

Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults

NCT00115960

RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study is to determine the safety of and immune response to an experimental HIV vaccine, HIV-1 gag DNA, with and without an IL-15 DNA adjuvant (at escalating doses of 100, 500, and 1500 mcg). This study will also test the safety of and immune response to the HIV-1 gag DNA vaccine plus IL-15 DNA adjuvant given with or without 2 other adjuvant-containing booster vaccines.

Timeline

Start
Primary completion
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject HIV-1 gag DNA Vaccine
Subject IL-15 DNA adjuvant Other / unclassified 100 ug
Subject IL-15 DNA adjuvant Other / unclassified 500 ug
Subject IL-15 DNA adjuvant Other / unclassified 1500 ug
Subject Rocakinogene Sifuplasmid Vaccine